BD Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results
Article excerpt
FRANKLIN LAKES, N.J., Nov. 5, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced results for its fiscal 2026 fourth quarter and full year, which ended September 30, 2026. "We delivered a strong fourth quarter, with 5.6% revenue growth and broad-based performance led by our key growth platforms," said Tom Polen, chairman, CEO and president of BD. "Fiscal 2026 was a defining year as we completed BD's transformation to a more focused MedTech company with separation of our Life Sciences business. We strengthened our core growth and expanded BD Excellence to elevate our commercial capabilities, accelerate innovation and drive greater productivity. We enter fiscal 2027 from a position of strength, with a portfolio built for durable performance and confidence in the long-term growth, earnings and cash-flow potential of New BD." Recent Business Highlights The company will hold its 2026 Investor Day on December 10th at the New York Stock Exchange. Additional information will be forthcoming. Basis of Presentation - Continuing Operations On February 9, 2026, the company completed the spin-off of BD's former Biosciences and Diagnostic Solutions business and the combination of the business with Waters Corporation ("Waters"). The historical results of the former Biosciences and Diagnostic Solutions business...
Keep reading with a free account
The rest of this article, and every signal for BD, is in your free account.
Extracted from this sentence
Fourth Quarter Fiscal 2026 Operating Results (Millions of dollars, except per share amounts) Three Months Ended September 30, Reported Change Foreign Currency Neutral Change 1 2026 2025 Revenues $ 5,274 $ 5,005 5.4 % 5.6 % Reported Diluted Earnings per Share $ 2.52 $ 1.20 110.0 % 109.2 % Adjusted Diluted Earnings per Share 1 $ 4.15 $ 3.26 27.3 % 27.3 % 1 Represents a non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures in the attached financial tables.